• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类药物使用障碍:医疗治疗选择。

Opioid Use Disorder: Medical Treatment Options.

机构信息

University of California-San Francisco, San Francisco General Hospital, San Francisco, CA, USA.

出版信息

Am Fam Physician. 2019 Oct 1;100(7):416-425.

PMID:31573166
Abstract

Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, patients are more likely to enter full recovery. Methadone and buprenorphine are opioid agonists that reduce mortality, opioid use, and HIV and hepatitis C virus transmission while increasing treatment retention. Intramuscular naltrexone is not as well studied and is harder to initiate than opioid agonists because of the need to abstain for approximately one week before the first dose. However, among those who start naltrexone, it can reduce opioid use and craving. Choosing the correct medication for a given patient depends on patient preference, local availability of opioid treatment programs, anticipated effectiveness, and adverse effects. Discontinuation of pharmacotherapy increases the risk of relapse; therefore, patients should be encouraged to continue treatment indefinitely. Many patients with opioid use disorder are treated in primary care, where effective addiction treatment can be provided. Family physicians are ideally positioned to diagnose opioid use disorder, provide evidence-based treatment with buprenorphine or naltrexone, refer patients for methadone as appropriate, and lead the response to the current opioid crisis.

摘要

阿片类药物使用障碍的发病率很高,且可能致命。2016 年,至少有 210 万 12 岁及以上的美国人患有阿片类药物使用障碍,2017 年约有 4.7 万名美国人死于阿片类药物过量。阿片类药物使用障碍是一种慢性复发性疾病,其治疗属于家庭医生的实践范围。通过适当的药物辅助治疗,患者更有可能完全康复。美沙酮和丁丙诺啡是阿片类激动剂,可降低死亡率、阿片类药物使用量以及艾滋病毒和丙型肝炎病毒的传播,同时提高治疗保留率。肌肉内注射纳曲酮的研究较少,且由于需要在第一剂前大约一周内禁欲,因此比阿片类激动剂更难启动。然而,对于开始使用纳曲酮的患者,它可以减少阿片类药物的使用和渴望。为特定患者选择正确的药物取决于患者的偏好、当地阿片类药物治疗方案的可用性、预期效果和不良反应。药物治疗的中断会增加复发的风险;因此,应鼓励患者无限期继续治疗。许多患有阿片类药物使用障碍的患者在初级保健中接受治疗,在那里可以提供有效的成瘾治疗。家庭医生是诊断阿片类药物使用障碍、提供丁丙诺啡或纳曲酮循证治疗、酌情转介患者接受美沙酮治疗以及领导应对当前阿片类药物危机的理想人选。

相似文献

1
Opioid Use Disorder: Medical Treatment Options.阿片类药物使用障碍:医疗治疗选择。
Am Fam Physician. 2019 Oct 1;100(7):416-425.
2
Medications for Opioid Use Disorder: A Guide for Physicians.阿片类物质使用障碍的药物治疗:医师指南
Mo Med. 2020 Jan-Feb;117(1):59-64.
3
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.阿片类药物使用障碍的药物治疗对死亡率的影响。
CNS Drugs. 2020 Jun;34(6):629-642. doi: 10.1007/s40263-020-00719-3.
4
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.将药物辅助治疗阿片类药物成瘾与移动健康相结合的效果:一项随机临床试验的研究方案
Trials. 2016 Dec 12;17(1):592. doi: 10.1186/s13063-016-1726-1.
5
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.在美国商业保险队列中,使用纳曲酮和丁丙诺啡药物治疗阿片类药物使用障碍时,起始治疗后出现药物过量。
Drug Alcohol Depend. 2019 Jul 1;200:34-39. doi: 10.1016/j.drugalcdep.2019.02.031. Epub 2019 May 3.
6
Medications for management of opioid use disorder.阿片类药物使用障碍的药物治疗。
Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105.
7
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.接受美沙酮、丁丙诺啡或植入式纳曲酮治疗的阿片类药物依赖患者的致命和非致命阿片类药物过量情况。
Int J Drug Policy. 2017 Aug;46:54-60. doi: 10.1016/j.drugpo.2017.05.039. Epub 2017 Jun 10.
8
Adjunctive memantine for opioid use disorder treatment: A systematic review.辅助美金刚治疗阿片类药物使用障碍:系统评价。
J Subst Abuse Treat. 2019 Dec;107:38-43. doi: 10.1016/j.jsat.2019.10.003. Epub 2019 Oct 20.
9
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.纳美芬被错误地用于减少接受丁丙诺啡替代疗法患者的酒精摄入量,导致急性阿片类药物戒断:急诊处理
J Clin Psychopharmacol. 2016 Feb;36(1):100-3. doi: 10.1097/JCP.0000000000000448.
10
Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.使用微量剂量方案,在不进行阿片类药物戒断期的情况下,将患有阿片类药物使用障碍的住院患者从美沙酮转为丁丙诺啡。
Pharmacotherapy. 2019 Oct;39(10):1023-1029. doi: 10.1002/phar.2313. Epub 2019 Aug 15.

引用本文的文献

1
The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention.阿片类疫苗作为治疗阿片类药物使用障碍和预防过量用药的一种新策略的发展。
Int J Neuropsychopharmacol. 2025 Feb 4;28(2). doi: 10.1093/ijnp/pyaf005.
2
Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens.在阿片类药物成瘾治疗中我们需要进行尿液药物筛查吗:一项关于自我报告与尿液药物筛查的观察性研究
Addict Behav Rep. 2024 Nov 27;21:100575. doi: 10.1016/j.abrep.2024.100575. eCollection 2025 Jun.
3
Multiomic Network Analysis Identifies Dysregulated Neurobiological Pathways in Opioid Addiction.
多组学网络分析确定阿片类药物成瘾中失调的神经生物学途径。
Biol Psychiatry. 2025 Jul 1;98(1):11-22. doi: 10.1016/j.biopsych.2024.11.013. Epub 2024 Nov 29.
4
Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder.盐酸纳美芬:对治疗酒精和阿片类物质使用障碍的潜在意义。
Subst Abuse Rehabil. 2024 Apr 3;15:43-57. doi: 10.2147/SAR.S431270. eCollection 2024.
5
A genome-wide association, polygenic risk score and sex study on opioid use disorder treatment outcomes.全基因组关联、多基因风险评分和性别对阿片类药物使用障碍治疗结果的研究。
Sci Rep. 2023 Dec 15;13(1):22360. doi: 10.1038/s41598-023-49605-0.
6
Male patients' preferences for opioid use treatment programs.男性患者对阿片类药物使用治疗方案的偏好。
BMC Psychiatry. 2023 Jun 16;23(1):440. doi: 10.1186/s12888-023-04939-x.
7
Ketogenic diet enhances the effects of oxycodone in mice.生酮饮食增强了羟考酮在小鼠体内的作用。
Sci Rep. 2023 May 9;13(1):7507. doi: 10.1038/s41598-023-33458-8.
8
An observational study on the use of long acting buprenorphine (ublocade) and a amper resistant PICC for utpatient IV antibiotic administration in atients with serious infections and pioid se isorder; The project.一项关于长效丁丙诺啡(ublocade)和耐安培外周静脉中心静脉导管在患有严重感染和阿片类物质使用障碍患者门诊静脉注射抗生素治疗中的应用的观察性研究;该项目。
Drug Alcohol Depend Rep. 2021 Dec 20;2:100020. doi: 10.1016/j.dadr.2021.100020. eCollection 2022 Mar.
9
The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.内源性阿片肽的前世今生:对其合成、时空动态的最新认识及其在酒精使用障碍中的临床影响。
Neuropharmacology. 2023 Mar 1;225:109376. doi: 10.1016/j.neuropharm.2022.109376. Epub 2022 Dec 11.
10
Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.NAQ作为一种用于治疗阿片类物质使用障碍的μ阿片受体部分激动剂的临床前特征及研发
ACS Pharmacol Transl Sci. 2022 Nov 2;5(11):1197-1209. doi: 10.1021/acsptsci.2c00178. eCollection 2022 Nov 11.